Valuation: Insmed Incorporated

Market Cap 31.01B 28.24B 26.02B 23.67B 44.41B 2,871B 46.67B 317B 126B 1,568B 116B 114B 4,922B P/E 2026 *
-87.5x
P/E 2027 * 202x
Enterprise Value 30.49B 27.77B 25.59B 23.28B 43.67B 2,823B 45.89B 311B 124B 1,542B 114B 112B 4,840B EV / Sales 2026 *
16.4x
EV / Sales 2027 * 10.1x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day-2.17%
1 week+16.65%
Current month+25.54%
1 month+50.29%
3 months+12.37%
6 months+29.03%
Current year-18.79%
1 week 118
Extreme 118
150
1 month 92.62
Extreme 92.625
150
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 11.31
Extreme 11.31
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Chief Tech/Sci/R&D Officer 62 19/12/2019
Chief Operating Officer 57 14/11/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
10/19/26 A Free

Director

6,139 0.0028%
10/19/26 A Free

Director

6,139 0.0028%
9/9/26 A Sell

Director

-25,000 0.0114%
Change 5-day change 1-year change 3-year change Capi.($)
-2.17%+16.65%-28.89%+479.93% 31.01B
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-6.57%-12.37%+34.03%-15.63% 21.45B
Average -1.89%-2.33%+33.16%+160.92% 42B
Weighted average by Cap. -1.74%-2.39%+31.94%+146.36%

Financials

2026 *2027 *
Net sales 1.86B 1.7B 1.56B 1.42B 2.67B 172B 2.8B 19.01B 7.56B 94.13B 6.98B 6.84B 295B 2.99B 2.72B 2.51B 2.28B 4.28B 277B 4.5B 30.55B 12.14B 151B 11.22B 10.98B 475B
Net income -352M -320M -295M -268M -504M -32.56B -529M -3.59B -1.43B -17.78B -1.32B -1.29B -55.81B 164M 149M 137M 125M 235M 15.17B 247M 1.67B 665M 8.28B 615M 602M 26B
Net Debt -514M -469M -432M -393M -737M -47.64B -774M -5.25B -2.09B -26.02B -1.93B -1.89B -81.66B -949M -864M -796M -724M -1.36B -87.88B -1.43B -9.69B -3.85B -48B -3.56B -3.49B -151B
Projected Income Statement - Annual - Insmed Incorporated
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
20/11/26 $141.33 -2.17% 6,216,094
19/11/26 $144.46 +20.58% 14,410,442
18/11/26 $119.80 -1.69% 1,944,159
17/11/26 $121.86 -0.83% 2,398,022
16/11/26 $122.88 +1.42% 2,233,188
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Insmed Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
141.33USD
Average target price
194.18USD
Spread / Average Target
+37.40%
  1. Stock Market
  2. Stocks
  3. INSM Stock